Αρχική World News FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma World News FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma Από Ogkologos - 8 Αυγούστου, 2025 860 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... 27 Ιανουαρίου, 2025 Get the Facts Before Using Online Information 11 Μαΐου, 2022 FDA Approves Second CAR T-Cell Therapy for Lymphoma 22 Μαΐου, 2018 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... 14 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines Growing the Cancer Research Pipeline by Expanding Opportunities Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each...